Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2010
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00831545 (Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-small Cell Lung Cancer.), which is not on this map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-small Cell Lung Cancer.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review.International journal of cancer · 2020Pooled it
- Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung cancer.Cancer medicine · 2018Pooled it
- Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.Journal of neuro-oncology · 2017Pooled it
- Phase II trial of patupilone in patients with brain metastases from breast cancer.Neuro-oncology · 2014Trial
- Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.Journal of neuro-oncology · 2012Trial
- Chinese Society of Clinical Oncology breast cancer expert consensus on the diagnosis and treatment of breast cancer brain metastasis (2025).Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Central Nervous System Metastases in Breast Cancer.Current treatment options in oncology · 2025Review
- CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2022Review
- The management of elderly patients with brain metastases from breast cancer.Translational cancer research · 2020Review
- Leptomeningeal Metastases.Current treatment options in oncology · 2018Review
- Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Neuro-oncology · 2017Review
- Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases.International journal of molecular sciences · 2016Review
- Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.Cancer immunology research · 2016Article
- Cancer and the metastatic substrate.Ecancermedicalscience · 2016Review
- Brain metastasis: new opportunities to tackle therapeutic resistance.Molecular oncology · 2014Review
- Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors.Journal of neuro-oncology · 2014Article
- Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.Autophagy · 2014Article
- Article
- Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Current approaches to the treatment of metastatic brain tumours.Nature reviews. Clinical oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrain metastases reduce survival because therapeutic options are limited. This phase II study evaluated the efficacy of single-agent therapy with alternating weekly, dose-dense temozolomide in pretreated patients with brain metastases prospectively stratified by primary tumor type.
methodsEligible patients had bidimensionally measurable brain metastases from histologically/cytologically confirmed melanoma, breast cancer (BC), or non-small-cell lung cancer (NSCLC). Prior chemotherapy, radiotherapy, and whole-brain radiotherapy (WBRT) were allowed. Patients received temozolomide 150 mg/m(2)/day (days 1-7 and 15-21 every 28- or 35-day cycle).
resultsIn the intent-to-treat population (N = 157; 53 melanoma, 51 BC, and 53 NSCLC), one patient had complete response, nine (6%) had partial responses, and 31 (20%) had stable disease in the brain. Median progression-free survival was 56, 58, and 66 days for melanoma, BC, and NSCLC, respectively. Median overall survival was 100 days for melanoma, 172 days for NSCLC, and not evaluable in the BC group. Thrombocytopenia was the most common adverse event causing dose modification or treatment discontinuation. Grade 4 toxic effects were rare.
conclusionsThis alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma. Combining temozolomide with WBRT or other agents may improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.